Document is current
Any future updates will be listed below
-
Authors
Lanza, Juliane S.
Hammoudi, Adele
De Chiara, Joanna
Surenaud, Mathieu
Kembou, Anaïs
Esposito, Michela
Zurawski, Sandra
Zurawski, Gerard
Centlivre, Mireille
Malissen, Bernard
Godot, Véronique
Lévy, Yves
Henri, Sandrine
Cardinaud, Sylvain
-
Funding
Funding for this research was provided by:
Agence Nationale de la Recherche (ANR-10-LABX- 77, ANR-10-LABX- 77, ANR-10-LABX- 77, ANR-10-LABX- 77, ANR-10-LABX- 77, ANR-10-LABX- 77, ANR-10-LABX- 77, ANR-10-LABX- 77, ANR-10-LABX- 77, ANR-10-LABX- 77, ANR-10-LABX- 77, ANR-10-LABX- 77, ANR-10-LABX- 77, ANR-10-LABX- 77)
- License Information
-
More Information
Article History
Received: 25 December 2024
Accepted: 30 June 2025
First Online: 25 July 2025
Competing interests
: Authors declare no financial or commercial conflicts of interest, except GZ and SZ are named inventors on patent filings for the use of antigens directed to LCs as vaccines (WO 2011/032161 A3; Vaccines directed to Langerhans cells; August 25, 2011), filed by Baylor Institute for Immunology Research (Dallas, TX, USA) and licensed to Inserm Transfert (Paris, France). AH, MS, VG, YL and SC are named inventors of Langerhans cells targeting HIV-1 vaccines, filed by Inserm and University Paris-Est Créteil Val-de-Marne (France) licensed to Inserm Transfert (International Procedure PCT/IB2024/000163; March 24, 2024).
